Why invest in GAVI?

in page functions

Five reasons why investing in vaccines and immunisation through our Alliance guarantees a high rate of return in lives and dollars


Four million future deaths can be averted between 2011 and 2015 through increased investments in vaccines

In its first 12 years, GAVI has helped developing countries to prevent over 5.5 million future deaths. Between 2011 and 2015, these countries have the potential to immunise 245 million children and avert an additional four million future deaths with GAVI-supported vaccines. This offensive is targeting:

  • the two biggest killers of children, pneumonia and diarrhoea, through accelerating the introduction of pneumococcal and rotavirus vaccines;
  • deadly and debilitating meningitis epidemics by supporting a new vaccine against meningitis A;
  • the introduction of human papillomavirus (HPV) vaccines that protect women against cervical cancer and vaccines against measles, rubella and yellow fever;
  • strengthened routine immunisation programmes as part of integrated health services.


The world cannot afford to miss the opportunity to deliver life-saving vaccines against the two biggest child killers

GAVI is working with developing countries to protect children from pneumonia and diarrhoea and help the world move toward achieving Millennium Development Goal four - reducing child mortality by two-thirds before 2015:

  • GAVI's programme support offers new and life-saving vaccines against pneumococcal and rotavirus disease;
  • More than two-thirds of all GAVI-supported countries have been approved for funding for pneumococcal, and almost half for rotavirus vaccines;
  • By the end of 2012, 24 developing countries had already started to introduce the pneumococcal vaccine with GAVI support; 12 countries had rolled out rotavirus vaccine with GAVI support.


GAVI support counts 100% towards G8 mother-child health commitments

In June 2010, the G8 reviewed the programmes of all major multilateral agencies to calculate how much core contributions to these agencies would impact on the Muskoka Initiative for Maternal, Newborn and Child Health. They concluded that donor investments in GAVI would count 100% towards maternal and child health.

Expanded immunisation coverage for children was ranked among the top five most cost-effective solutions to major global challenges by Copenhagen Consensus (2008), an international think tank.

Right to health

Poor children have the same right to access life-saving vaccines as children from wealthier backgrounds

Yet, on average, 15 years separate a vaccine's discovery and its introduction in low-income countries. This means more than 22.6 million of all children worldwide do not receive the life-saving vaccines that are taken for granted on vaccination cards in most industralised countries. Investing in GAVI and vaccines will help redress this inequity.


Multilateral aid reviews by the governments of Australia , Sweden and the United Kingdom and the Multilateral Organisation Performance Assessment (MOPAN) all place GAVI among the top performers in terms of value for money, organisational strengths and contribution to development

  • The GAVI business model fosters a competitive vaccine market by pooling demand from developing countries and providing predictable financing to meet demand, attracting new manufacturers from emerging economies and increasing competition to drive down prices;
  • GAVI's co-financing scheme has increased country ownership of immunisation programmes;
  • GAVI support is aligned with national immunisation and health plans in line with the principles of aid effectiveness;
  • GAVI's success is driven by an inclusive partnership with the key stakeholders in global immunisation;
  • GAVI has pioneered new ways of financing development: the International Finance Facility for Immunisation (IFFIm) leverages long-term donor commitments to issue bonds on the capital markets, contributing to the certainty of funding that underpins long-term vaccine programmes; the pneumococcal Advance Market Commitment (AMC) has accelerated the introduction of pneumococcal vaccines in developing countries within months of their development and at lower prices .

How you can help

  • Seize opportunities to spread the message through articles in the media, blogs and public presentations.
  • Spread the word via email and social media sites.
  • Make sure GAVI's key messages about the power of immunisation and the opportunity to save lives are in all your communications: newsletters, website, blog, etc.
  • Contact your local politician and express support for immunisation and full funding for GAVI.
  • If you are from a civil society organisation (CSO), join the GAVI CSO constituency.
  • Share your stories of the power of immunisation and its impact with us. We’ll share them with others.
  • Make a donation to GAVI.
  • Sign up for GAVI's Facebook page and share it with your friends.
  • Follow GAVI on Twitter and re-tweet.
  • Subscribe to GAVI’s Immunisation insights newsletter.

More on this topic

close icon

modal window here